FOLR1 and peritoneum cancer: The approval was based on preliminary results of the SORAYA study, also known as Study 0417 (NCT04296890), a single-arm trial of 106 patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (n = 104).